Dr. Franzusoff joined PACT Pharma in 2017 to develop personalized adoptive T cell therapies using precision genome-engineered patient T cells that target confirmed tumor neoepitopes. Alex has actively contributed to significant advances in immuno-oncology (I-O). As SVP R&D at Bavarian Nordic, his team’s work on cancer immunotherapy was key to the $1B deal with BMS in 2015. Dr. Franzusoff earlier co-founded GlobeImmune, where he served as VP R&D, developing immunotherapy against cancer & infectious diseases. In Boston, Alex was CEO & Director for AZTherapies, developing Alzheimer’s combination drug therapies for Phase 3 studies. He previously led the venture-backed Permeon Biologics developing intracellular biologics. Alex was tenured faculty at the Univ. of Colorado Medical School until 2004.
Dr. Franzusoff received his PhD in Biochemistry from SUNY Stony Brook, NY. Dr. Franzusoff trained as a postdoctoral fellow with the Nobel Laureate, Dr. Randy Schekman, at UC Berkeley.